Literature DB >> 11246281

Treatment of pemphigus vulgaris and pemphigus foliaceus: experience with 71 patients over a 20 year period.

N C Fernandes1, M Perez.   

Abstract

Forty one cases of pemphigus vulgaris and thirty cases of pemphigus foliaceus were investigated at Hospital Universitário Clementino Fraga Filho from 1978 to 1999. They were divided into two treatment groups: one group received up to 100 mg of oral prednisone daily and the other group received >120 mg daily. The dose up to 100 mg provided good initial control of pemphigus vulgaris and pemphigus foliaceus and did not increase the mortality rate associated to disease. The dose >120 mg induced higher morbidity. These data allowed us to establish a regimen of oral prednisone (1-2 mg/kg/daily) with maximum of 120 mg daily in the treatment of pemphigus vulgaris and pemphigus foliaceus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246281     DOI: 10.1590/s0036-46652001000100007

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  3 in total

1.  Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis.

Authors:  Alex M Rokni; Marissa Ayasse; Adnan Ahmed; Lauren Guggina; Robert W Kantor; Jonathan I Silverberg
Journal:  Arch Dermatol Res       Date:  2022-03-09       Impact factor: 3.017

2.  Pulse therapy in pemphigus: report of 11 cases.

Authors:  Nurimar Conceição Fernandes; Mariana Menezes
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

Review 3.  Emerging treatment options for the management of pemphigus vulgaris.

Authors:  Khalaf Kridin
Journal:  Ther Clin Risk Manag       Date:  2018-04-27       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.